Eisai: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income, 2005
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure by Business Area
    • Capital Expenditure by Business Area
    • R&D Expenditure
    • R&D Expenditure and Capital Expenditure
  • Divisional Performance
    • Sales By Business Area
    • Sales by Business Area
    • Operating Income (Loss) by Business Area
    • Operating Income (Loss) by Business Area
    • Total Assets by Business Area
    • Total Assets by Business Area, 2005
  • Geographic Performance
    • Sales by Destination
    • Sales by Destination, 2005
    • Sales by Origin
    • Sales by Origin
    • Operating Income (Loss) by Geographical Area
    • Total Assets by Geographical Area
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
    • Employees by Geographic Segment, 2005
    • Employees and Productivity
• Product/R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
  • Sales Forecasts
    • Sales of Current Major Products (2001A-2010E)
• Conclusions

PRODUCT PORTFOLIO/RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Sales of Major Products, 2005
• R&D Pipeline

• Neurology - Products
  • Major Launched Products
  • Aricept
    • Sales
    • Key Markets/Indications/Formulations
    • Further development
    • Patents/Generic Competition
    • Competitor Products
    • Sales Forecast
  • Aricept Sales (2000A-2010E)
  • Methycobal/Nabolin S
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor products
    • Sales Forecast
  • Methycobal Sales (2000A-2010E)
  • Myonal
    • Sales
    • Key Markets/Indications
    • Competitor Products
    • Sales Forecast
• Myonal Sales (2000A-2010E)
• Zonegran
• Other Neurology Products

• Neurology - R&D
  • Agilect
    • Clinical Trial Results
  • E2007
  • E2014
  • E2070
  • Inovelon
    • Clinical Trial Results
• Neurology - Summary
  • Growth Potential
  • Limiting Factors
• Gastroenterology - Products
  • Major Launched Products
  • Aciphex/Pariet
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Patents/Lawsuits/Generic Competition
    • Competitor Products
    • Sales Forecast
  • Aciphex/Pariet sales (2000A-2010E)
  • Selbex
    • Sales
    • Key Markets/Indications
    • Competitor Products
    • Patents/Lawsuits
    • Sales Forecast
  • Selbex Sales (2000A-2010E)
• Gastroenterology - R&D
  • E3620
• Gastroenterology - Summary
  • Growth Potential
  • Limiting Factors
• Cardiovascular and Respiratory - Products
  • Major Launched Products
  • Azeptin
    • Sales
    • Key Markets/Indications
    • Competitor Products
    • Sales Forecast
  • Azeptin Sales (2000A-2010E)
  • Nitrol-R
    • Sales
    • Competitor Products
    • Sales Forecast
  • Nitrol-R Sales (2000A-2010E)
  • Cleactor
• Cardiovascular and Respiratory - R&D
  • E2051
  • E5555
  • Tambocor
• Cardiovascular and Respiratory - Summary
  • Growth Potential
  • Limiting Factors
• Metabolic - Products
  • Major Launched Products
  • Glakay/KayTwo
    • Sales
    • Key Markets/Indications
    • Competitor Products
    • Sales Forecast
  • Glakay/KayTwo sales (2000A-2010E)
  • Glucagon G Novo
    • Sales
    • Key Markets/Indications
    • Sales Forecast
  • Glucagon G Novo sales (2000A-2010E)
• Metabolic - R&D
  • E3030
  • KES524
    • Clinical Trial Results
• Metabolic - Summary
  • Growth Potential
  • Limiting Factors
• Diagnostics - Products
  • Major Launched Products
  • Iomeron
    • Sales
    • Key Markets/Indications
    • Sales forecast
    • Iomeron Sales (2000A-2010E)
• Diagnostics - R&D
  • E7210
• Diagnostics - Summary
• Anti-infectives - Products
  • Major Launched Products
  • Rulid
    • Sales
    • Key Markets/Indications
• Anti-infectives - R&D
  • Eritoran
    • Clinical Trial Results
  • Ravuconazole (ER-30346)
• Anti-infectives - Summary
  • Growth Potential
  • Limiting Factors
• Oncology - R&D
  • E0167
  • E7080
  • E7389
    • Clinical Trial Results
  • E7820
  • Indislam
  • E7010
  • E7107
  • E7934
• Oncology - Summary
  • Growth Potential
  • Limiting Factors
• Other - Products
  • Actonel
• Other - R&D
  • Adalimumab (D2E7)
  • E6040
  • Iguratimod

APPENDIX 1- FINANCIAL PERFORMANCE

• Full Year Results 2005
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Abbott
  • 21st June 1999
  • 5th July 2000
  • 27th April 2004
  • 11th April 2005
• Dainippon Sumitomo Pharma
  • 28th March 2005
• Elan Corporation plc
  • 29th September 2000
  • 27th April 2004
  • 9th February 2006
• GlaxoSmithKline plc
  • 1st April 2004
  • 26th May 2005
• Janssen Pharmaceutica
  • 15th April 1997
  • 7th January 2004
• Novartis
  • 6th February 2004
• Pfizer
  • 28th November 1994
  • 25th July 2002
  • 2nd January 2003
  • 28th September 2005
• sanofi-aventis/Ajinomoto
  • 20th March 2002
  • 12th September 2005
• Teva Pharmaceutical Industries Ltd
  • 15th May 2003
• TorreyPines Therapeutics Inc
  • 18th March 2005
• Toyama Chemical Co Ltd
  • 30th September 1998
• Wyeth
• Others

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

• Subsidiaries
  • Major Domestic Subsidiaries
  • Major North American Subsidiaries
  • Major European Subsidiaries
  • Major Asian Subsidiaries
• Joint-Venture Companies

APPENDIX 6 - PRODUCT INDEX